November 12, 2024 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today its engagement in a collaboration with the SKIN Research Group of the Department of Dermatology at the Vrije Universiteit Brussel (VUB)/ University hospital in Brussels (UZ Brussels) for a study geared toward predicting atopic dermatitis (a special form of eczema) and concomitant atopic diseases, such as asthma and hay fever in infants.
SciBase is excited to announce a new collaboration aimed at revolutionizing early detection of atopic diseases in infants through the use of Electrical Impedance Spectroscopy (EIS) technology. This partnership seeks to unlock the potential of Nevisense to predict an infant's risk of developing these conditions, empowering researchers with critical insights early in a child's life. The data gathered will play a key role in developing an innovative product that could pave the way for improved healthcare outcomes for children worldwide. The collaboration will start immediately and will include hundreds of newborn children enrolled in the DIANA birth cohort who will be followed for 2 years.
Inge Kortekaas Krohn, assistant professor SKIN Research Group comments:
‘’Early detection of a child that is at risk of developing atopic dermatitis and subsequent adequate preventive measures can reduce disease burden and further progression to other atopic diseases like food allergy, allergic asthma or allergic rhinitis. Therefore, the present collaboration holds the potential to improve prediction, prevention and the prognosis of children at risk for development of eczema and may have clinical relevance for allergic diseases other than atopic dermatitis as well.”
“We are thrilled about the potential this study holds to positively impact children and families, giving them the opportunity for a healthier start in life. At SciBase, our mission is to advance the prediction and prevention of diseases, and this collaboration aligns perfectly with our core values. The clinical products that may emerge from this partnership reflect our ongoing commitment to improving health outcomes for future generations. This study, as well as our separate collaboration with Kenvue, further reinforces our dedication to improving health outcomes for this patient population”, says Pia Renaudin CEO SciBase.
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The cash flow from current operations was negative in the amount of TSEK 16,745 (17,827).
The gross margin was 75.7% (68.2%).
Electrode sales volume increased by 2% and was 17,210 (16,922) units. Repeat sales of electrodes to existing customers decreased by 7% as Q3-23 included large electrode orders prior to a price increase.
January - September in figures
Net sales were TSEK 21,107 (17,481), +21%.
The loss after tax was TSEK 43,663 (35,044).
The loss per share was SEK 0.27 (0.34).
The cash flow from current operations was negative in the amount of TSEK 44,835 (34,633).
The gross margin was 72.0% (67.5%).
Electrode sales volume increased by 13% and was 45,078 (39,866) units. Repeat sales of electrodes to existing customers increased by 10%.
Important events during the quarter
Overall sales increased by 16% (+17, before currency effects). Sales in Germany within the skin cancer segment decreased by 8%(6% in local currency) following some customers building up inventory in Q3-23. Sales in the US skin cancer market increased by 187% while the sales within the skin barrier segment increased by 102%.
In the US aConsensus report by leading US clinicians assessing technologies for melanoma detection and management was published. The report concluded that the Nevisense AI-driven technology can significantly enhance early melanoma detection.
The National Institutes of Health (NIH), one of the world’s foremost medical research centers and a part of the U.S. Department of Health and Human Services, purchased Nevisense for research on the skin barrier. This sale represents a major milestone for SciBase and demonstrates the high quality and innovative nature of Nevisense for research in this area.
SciBase continued to expand in the US with new customers in new regions.
SciBase announced the change of Certified Adviser from Vator Securities to Carnegie Investment Bank AB (publ).
Important events after the end of the period
A Nomination Committee has been appointed for SciBase Holding’s Annual General Meeting in 2025.
SciBase initiates sales collaboration in Italy.
SciBase decides on a directed issue of approximately SEK 22.5 million and a rights issue of up to approximately SEK 59.3 million.
Oct 1, 2023 -
July 1 - Sep 30
Jan 1 - Sep 30
Sep 30, 2024
Jan 1 - Dec 31
THE GROUP
2024
2023
2024
2023
Rolling-12
2023
Net sales, SEK ths
8 408
7 248
21 107
17 481
26 870
23 245
Gross margin, %
75,7%
68,2%
72,0%
67,5%
72,3%
69,0%
Equity/Asset ratio, %
67,6%
72,4%
67,6%
72,4%
70,4%
66,9%
Net indebtness, multiple
0,48
0,38
0,48
0,38
0,42
0,49
Cash equivalents, SEK ths
24 714
52 353
24 714
52 353
24 714
34 121
Cashflow from operating activities, SEK ths
-16 475
-17 827
-44 835
-34 633
-62 187
-51 984
Earnings per share (before and after dilution), SEK
-0,08
-0,11
-0,27
-0,34
-0,42
-0,51
Shareholder's equity per share, SEK
0,17
0,50
0,23
0,58
0,32
0,40
Average number of shares, 000'
219 538
119 831
164 146
104 029
153 067
107 980
Number of shares at closing of period, 000'*
219 538
119 831
219 538
119 831
219 538
119 831
Share price at end of period, SEK
0,48
1,24
0,51
1,24
0,51
0,83
Number of sold electrodes, pieces
17 210
16 922
45 078
39 866
57 132
51 920
Average number of employees
29
23
27
22
27
23
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on November 12, 2024.
This report has been comprehensively reviewed by the Company’s auditors.
For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
SWEDEN, - October 30, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announces today the collaboration with Kilabs srl, an Italian Company with expertise in dermatology, which now will be able to offer access to better diagnostics of skin cancer in Italy.
Kilabs is dedicated to advancing research, development and access to cutting-edge solutions in specialized medical fields. SciBase will adapt Nevisense for the Italian market, which is a regulatory prerequisite for the launch which is expected to take place in the first half of 2025. However, Kilabs will already now start preparing the market ahead of the planned launch. Skin cancer is a growing problem in Italy and access to Nevisense will significantly increase the possibility of early detection and improved care. Data in Italy show that mortality has increased, particularly among men.
Michelangelo Simonelli, CEO at Kilabs, is spearheading the introduction of Nevisense in Italy Under Simonelli's leadership leveraging on a team of recognized experts in the field such as Alessandro Cappella and Giuseppe Romano, Kilabs is working to integrate Nevisense into clinical practice, offering a more accurate and non-invasive method for early melanoma detection, which could significantly improve patient outcomes in the field of dermatology. This initiative underscores Kilabs' commitment to innovation and improving healthcare standards in Italy.
" I am really very proud to be part of a lifesaving project to address the critical issue of melanoma in Italy. I firmly believe Kilabs will play a crucial role in securing appropriate deployment of Nevisense thanks to our high expertise and introduction in the field", says Michelangelo Simonelli CEO of Kilabs Srl.
"I look forward to a very exciting collaboration. During the year, we have met with Italian doctors and tested the interest in the technology together with our partner, and I look forward to being able to offer patients in Italy better diagnostics and care together with Kilabs. Kilabs will start preparing the market now to be ready to launch Nevisense when the regulatory adjustments are in place. We will thus be able to give more patients access to Nevisense", says Pia Renaudin, CEO of SciBase.
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
About Kilabs
Kilabs is an organization dedicated to advancing research, development and access to cutting-edge solutions in specialized medical fields. https://www.kilabspharma.it/en/
SWEDEN, - Oct 21, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders will attend a leading US dermatology conference, Fall Clinical, to further enhance the clinical adoption and market expansion of Nevisense. The Fall Clinical conference attracts more than 1,100 clinicians looking to bridge gaps within the detection and diagnosis of melanoma clinical pathway. The conference offers comprehensive workshops and sessions led by top dermatology experts highlighting the latest advances in the diagnoses and treatment of various conditions and diseases. Nevisense will be included in several sessions focused on integrating technology into the melanoma detection and diagnostic clinical pathway.
SciBase continues to expand geographically in the US with new practices added in Maryland, Colorado and as recently published Pennsylvania. The Fall Clinical conference will provide an opportunity to further extend the US footprint and provide new customers with Nevisense. Nevisense is today the only FDA approved, non-invasive option for the detection of melanoma at an early stage when the disease is highly curable.
The new consensus report that was published in the JDD (September 2024 issue) will also be presented at the 44th annual Fall Clinical Dermatology Conference (“Fall Clinical 2024”). The consensus report evaluated several technologies for melanoma diagnosis and supports the use of Nevisense for its ability to significantly enhance clinician’s diagnostic assessment of atypical moles by non-invasively providing them with critical information at point of care.
“It is very encouraging to see that our recently added resources already are expanding our geographical footprint in the US, and we have recently opened up new markets in Pennsylvania, Maryland and Colorado. We are excited to continue this momentum during the Fall Clinical 2024 conference. SciBase is proud to support and attend the Fall Clinical 2024 conference and we look forward to engaging with our current customers as well as establishing new customers to further our mission of providing both clinicians and patients with improved outcomes and to positively impact the betterment of patient care.,” said Pia Renaudin, CEO of SciBase.
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
The following people have been appointed as members of SciBase Holding’s nominating committee for the Annual General Meeting in 2025:
Anders Bladh (Ribbskottet AB),
Fredrik Mattsson (Ejendals AB)
Dharminder Chahal (VanHerk Group),
Jesper Høiland (Chairman of the Board).
The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on June 13, 2024.
The Annual General Meeting of SciBase Holding AB (publ) will be held on May 21, 2025 in Stockholm.
Shareholders who wish to have an item considered by the nominating committee can do this in writing to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm or by e-mail to [email protected] Att: Chairman of the Board (who is the convenor of the nominating committee).
Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.
Stockholm, October 14, 2024
SciBase Holding AB (publ)
For more information, please contact: Jesper Høiland, Chairman of the board, phone +45 612 207 30
Michael Colérus, CFO, phone +46 70 341 34 72
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase and Nevisense
SciBase is a global medical technology company, specializing on early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reportsvisit: http://investors.scibase.se/en/pressreleases
SWEDEN, - Sept 27, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], pioneering prevention and prediction in dermatologydisorders is pleased to announce the completion of a milestone sale of Nevisense, a leading skin barrier research device, to the National Institutes of Health (NIH), one of the world's foremost medical research centers and a part of the U.S. Department of Health and Human Services. This sale represents a major milestone for SciBase and demonstrates the high quality and innovative nature of Nevisense for research.
The device will be used to conduct research on the microbiome and its interactions in atopic dermatitis (AD), exploring how the microbiome may unearth new treatments for AD.
“The fact that this prestigious governmental institution has chosen to use Nevisense in their research speaks volumes about the credibility and reliability of our product” says Pia Renaudin, CEO of SciBase. “The skin barrier research market is experiencing a rapid rise in interest, and the research in this space can directly improve the lives of millions of people worldwide. We are confident that the use of our device by the NIH will lead to groundbreaking discoveries and advancements in the field of dermatology.”
Nevisense is, apart from being able to detect skin cancer, also designed to analyze skin barrier function with the highest accuracy and robustness available, making it an essential tool for researchers. To date, studies have included Nevisense to study skin disorders, investigate environmental irritants and their effect on skin health, and analyze skin barrier dysfunction as it relates to allergies.
For more information on Nevisense for research and SciBase's medical products, visit www.scibase.com or contact Jeremy Bost at [email protected] .
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing on early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reportsvisit: http://investors.scibase.se/en/pressreleases
SWEDEN, - Sept 26, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], pioneering prevention and prediction in dermatology announces today a partnership with Seraly Dermatology in Pittsburgh, Pennsylvania. The strategic collaboration will allow SciBase to continue to broaden access of the Nevisense test to patients across the US, and further their commitment to the early detection of melanoma, when the disease is almost 100% curable. Seraly Dermatology will integrate several Nevisense systems into their skin cancer detection workflow.
“Melanoma is the deadliest form of skin cancer and catching it early is key to survival. At Seraly Dermatology, we believe in providing our patients with the most advanced personalized care. For these reasons, we are keen to integrate the Nevisense test into our melanoma detection workflow. The Nevisense technology non-invasively analyzes the cellular structure of a patient’s atypical moles right at point of care. This can help us not only personalize that patient’s care but also improve clinical outcomes by practicing the earliest melanoma detection possible” says Mark Seraly, MD, Board-Certified Dermatologist, founder and CEO of Seraly Dermatology.
”We are thrilled to commence a partnership with Seraly Dermatology Their focus on individual patient care is one of many reasons we are proud to partner with them. I’m also pleased to see that our recent U.S. team expansion is already having a positive impact on the U.S. market by increasing access of the Nevisense test to more patients in new geographic areas”, says Pia Renaudin, CEO of SciBase.
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing on early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reportsvisit: http://investors.scibase.se/en/pressreleases
Consensus reached by top US clinicians assessing technologies for melanoma detection and management
The report concludes that the Nevisense AI-driven technology can significantly enhance early melanoma detection
SWEDEN, - Sept 02, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], pioneering prevention and prediction in dermatology announces that key US clinicians and scientists reached consensus on Nevisense and how it can significantly enhance the diagnostic assessment and clinical decision-making for early melanoma at point of care. Nevisense is an AI-driven, non-invasive technology, and the only FDA-approved device for early skin cancer detection.
The consensus report evaluated several technologies for melanoma diagnosis and supports the use of Nevisense for its ability to significantly enhance clinician’s diagnostic assessment of atypical moles by non-invasively providing them with critical information at point of care. The report was published in the Journal of Drugs in Dermatology (JDD) – a peer-reviewed, dermatology journal. The report co-authors included top US clinicians such as Seemal R. Desai, MD, Keyvan Nouri, MD, Aaron S. Farberg, MD, Gary Goldenberg, MD, Mark Lebwohl, MD, and Darrell Rigel, MD, MS, Brian Berman, MD, PhD, Brad Glick, DO, MPH, Mark Nestor, MD, PhD, MBA, and Theodore Rosen, MD.
“I am so excited that this renowned panel of leading dermatologists has endorsed Nevisense as an important tool for early detection of melanoma. This is a significant step forward for SciBase in our US commercialization process” says Pia Renaudin, CEO of SciBase.
” Melanoma is one of the top 5 most common cancers in the US and is the main cause of skin cancer deaths in the United States. Early detection is critical to survival and one of the few ways to improve clinical outcomes for patients. With melanoma, timing and the earliest detection possible can make a significant positive impact on survival rates and outcomes. For these reasons, we as clinicians can provide our patients with AI-powered Nevisense, which is an advanced technology that enhances early detection while easily integrating at the point-of-care”, said Dr. Darrell Rigel, board-certified dermatologist, Clinical Professor of Dermatology Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, Adjunct Professor, UT Southwestern Medical School, Consultant Dermatologist, Cooper Clinic. Dr. Rigel served as President of the American Academy of Dermatology, the American Academy of Dermatology Association, the American Society for Dermatologic Surgery and the American Dermatological Association, as a Director of the American Board of Dermatology, and is the current Chair of SkinPAC (the American Academy of Dermatology Association’s political action committee).
"Nevisense is a powerful combination of human intelligence and artificial intelligence working together to improve clinical outcomes. At Goldenberg Dermatology, we strive to provide our patients with the highest standard of care with the most advanced technology. Nevisense helps clinicians identify more atypical pigmented skin lesions, which in turn helps increase detection rates. The clinically proven and validated science, and ease of practical integration were all key to reaching consensus", said Dr. Gary Goldenberg, board certified dermatologist and dermatopathologist, CEO and founder of Goldenberg Dermatology PC, and Assistant Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai Hospital in New York City.
The article can be found here : https://jddonline.com/articles/advances-in-technology-melanoma-diagnosis-prognosis-an-expert-consensus-panel-S1545961624P8365X/
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN, 21 August 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase], a leading developer of augmented intelligence-based solutions for skin, hereby announces change of Certified Adviser from Vator Securities to Carnegie Investment Bank AB (publ).
SciBase has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will assume the role of Certified Adviser effective from September 1, 2024. Until then, Vator Securities will continue to act as the Certified Adviser for the company.
For additional information, please contact: Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
The cash flow from current operations was negative in the amount of TSEK 15,179 (13,054).
The gross margin was 69.1% (65.3%).
Electrode sales volume increased by 24% and was 14,106 (11,330) units. Repeat sales of electrodes to existing customers increased by 22%.
January - June in figures
Net sales were TSEK 12,699 (10,234), +24%.
The loss after tax was TSEK 25,911 (22,258).
The loss per share was SEK 0.19 (0.31).
The cash flow from current operations was negative in the amount of TSEK 28,360 (16,805).
The gross margin was 69.5% (67.0%).
Electrode sales volume increased by 21% and was 27,868 (22,944) units. Repeat sales of electrodes to existing customers increased by 23%.
Important events during the quarter
Overall sales increased by 31% (+30, before currency effects). Sales in Germany within the skin cancer segment increased by 12%(11% in local currency). Sales in the US skin cancer market increased by 468% while the sales within the skin barrier segment increased by 7%.
SciBase resolved on a directed issued of approximately SEK 33 million and a rights issue of approximately SEK 15 million and postponed the Annual General Meeting and publication of the interim report for the first quarter of 2024.
SciBase published a prospectus and the summons to an EGM and the AGM.
SciBase announced a new partnership with Al Shirawi Healthcare solutions for the distribution of Nevisense in the UAE.
SciBase published the outcomes in the directed issue, were MSEK 33 were subscribed for and in the rights offering were MSEK were subscribed for corresponding to a subscription rate of 61%.
New German study shows Nevisense significantly improves dermatologists’ clinical decisions.
SciBase launched the eBarrier Score, the First AI-Driven Skin Barrier Assessment tool for research and Cosmetic Testing.
SciBase received the first order in Austria.
US organization strengthened with experienced leader in dermatology.
Partnership established with a large health care group in Los Angeles, Unified Health, and SciBase receives a first order.
The AGM was held on June 13th, new chairman of the Board appointed.
Important events after the end of the period
No events of significant nature have occurred after the end of the period.
Financial overview
July 1, 2023 -
Apr 1 - June 30
Jan 1 - June 30
June 30, 2024
Jan 1 - Dec 31
THE GROUP
2024
2023
2024
2023
Rolling-12
2023
Net sales, SEK ths
6 641
5 085
12 699
10 234
25 710
23 245
Gross margin, %
69.1%
65.3%
69.5%
67.0%
70.0%
69.0%
Equity/Asset ratio, %
71.8%
73.7%
71.8%
73.7%
72.9%
66.9%
Net indebtness, multiple
0.39
0.36
0.39
0.36
0.37
0.49
Cash equivalents, SEK ths
43 271
70 874
43 271
70 874
43 271
34 121
Cashflow from operating activities, SEK ths
-15 179
-13 054
-28 360
-16 805
-63 539
-51 984
Earnings per share (before and after dilution), SEK
-0.08
-0.16
-0.19
-0.31
-0.46
-0.51
Shareholder's equity per share, SEK
0.28
0.60
0.39
0.75
0.49
0.40
Average number of shares, 000'
186 303
119 831
136 449
96 129
128 140
107 980
Number of shares at closing of period, 000'*
219 538
119 831
219 538
119 831
219 538
119 831
Share price at end of period, SEK
0.51
1.19
0.51
1.19
0.51
0.83
Number of sold electrodes, pieces
14 016
11 330
27 868
22 944
56 844
51 920
Average number of employees
27
22
27
21
26
23
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 21, 2024.
This interim report report has not been subject to review by the Company’s auditors
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For more information, please contact: Pia Renaudin, CEO SciBase Tel: +46 73 206 98 02 Email: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
